Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Regenicin Inc. (RGIN : OTC)
 
 • Company Description   
Regenicin, Inc is a development stage biotechnology company primarily focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company's product candidate includes PermaDerm that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns and wounds. The candidate uses biomedical polymer to act as a connective agent in the skin generation process. The Company's prime focus is development of therapeutics in the areas of diabetes, chronic wounds, including ulcers, adult stem cell therapies and reconstructive surgery applications. Regenicin, Inc is headquartered in New York, New York.

Number of Employees: 3

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.00 Daily Weekly Monthly
20 Day Moving Average: 1,850 shares
Shares Outstanding: 153.77 (millions)
Market Capitalization: $0.31 (millions)
Beta: 0.67
52 Week High: $0.03
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -86.11% -84.36%
12 Week -85.51% -84.07%
Year To Date -80.00% -75.56%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10 HIGH COURT
-
LITTLE FALLS,NJ 07424
USA
ph: 973-557-8914
fax: -
None http://www.regenicin.com
 
 • General Corporate Information   
Officers
Randall McCoy - Chief Executive Officer; President and Director
John J. Weber - Principal Financial and Accounting Officer; and Di
J. Roy Nelson - Chief Science Officer
Craig Eagle - Director
Craig Eagle - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75887Q102
SIC: 3841
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/23/22
Share - Related Items
Shares Outstanding: 153.77
Most Recent Split Date: (:1)
Beta: 0.67
Market Capitalization: $0.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -13,783.47
09/30/21 - -15,931.94
Current Ratio
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Quick Ratio
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -0.03
09/30/21 - -0.03
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©